WO2000000628B1 - Replication-defective recombinant adenovirus with mutated major late promoter - Google Patents

Replication-defective recombinant adenovirus with mutated major late promoter

Info

Publication number
WO2000000628B1
WO2000000628B1 PCT/US1999/014333 US9914333W WO0000628B1 WO 2000000628 B1 WO2000000628 B1 WO 2000000628B1 US 9914333 W US9914333 W US 9914333W WO 0000628 B1 WO0000628 B1 WO 0000628B1
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant adenovirus
mlp
recombinant
adenoviral
mutation
Prior art date
Application number
PCT/US1999/014333
Other languages
French (fr)
Other versions
WO2000000628A1 (en
Inventor
Douglas E Brough
Imre Kovesdi
Original Assignee
Genvec Inc
Douglas E Brough
Imre Kovesdi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0301318A priority Critical patent/HUP0301318A2/en
Priority to EP99930675A priority patent/EP1088092A1/en
Priority to IL14027499A priority patent/IL140274A0/en
Priority to AU47163/99A priority patent/AU4716399A/en
Priority to CA002332181A priority patent/CA2332181A1/en
Priority to BR9911539-5A priority patent/BR9911539A/en
Application filed by Genvec Inc, Douglas E Brough, Imre Kovesdi filed Critical Genvec Inc
Priority to PL99345517A priority patent/PL345517A1/en
Priority to MXPA00012617A priority patent/MXPA00012617A/en
Priority to JP2000557381A priority patent/JP2002519036A/en
Publication of WO2000000628A1 publication Critical patent/WO2000000628A1/en
Publication of WO2000000628B1 publication Critical patent/WO2000000628B1/en
Priority to US09/748,044 priority patent/US6458578B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The present invention provides a recombinant adenovirus having a genome with a deficiency in the E1 region and a mutation in the MLP. The invention also provides stocks of such viruses and compositions including the inventive viruses. The invention also provides cell lines for propagating the recombinant adenoviruses.

Claims

AMENDED CLAIMS[received by the International Bureau on 10 January 2000 (10.01.00); original claims 1-19 replaced by amended claims 1-19 (2 pages)]
1. A recombinant adenovirus comprising a genome with a deficiency in the El region and a mutation in the MLP such that the MLP is less active within a cell other than a packaging cell, and wherein either (a) the genome further comprises a nucleic acid encoding a functional adenoviral DNA polymerase or (b) the mutation renders the MLP responsible to an altered TBP.
2. The recombinant adenovirus of claim 1 , wherein the genome further comprises a deficiency in the E3 region.
3. The recombinant adenovirus of claim 1 or 2, wherein the genome comprises a nucleic acid encoding a functional adenoviral DNA polymerase.
4. The recombinant adenovirus of any of claims 1 -3, wherein the mutation in the MLP is within a control element of the MLP selected from the group of control elements consisting of the inverted CAAT box, the UPE, the TATA box, DEI, and DE2.
5. The recombinant adenovirus of any of claims 1 -4, wherein the mutation renders the MLP responsible to an altered TBP.
6. The recombinant adenovirus of any of claims 1-5, wherein the mutation in the MLP places the MTLU under the control of an exogenous inducible promoter.
7. The recombinant adenovirus of claim 6, wherein the exogenous promoter is the NF-AT1 response sequence.
8. The recombinant adenovirus of any of claims 1 -7, wherein the genome comprises a plurality of mutations in the MLP.
9. The recombinant adenovirus of claim 8, wherein each of the mutations in the MLP is within a control element of the MLP selected from the group of control elements consisting of the inverted CAAT box, the UPE, the TATA box, DE 1 , and DE2. 17
10. The recombinant adenovirus of any of claims 1 -9, further comprising a non-native nucleic acid for expression.
11. A stock comprising the recombinant adenovirus of any of claims 1 - 10.
12. The stock of claim 11, which is substantially free of RCAs.
13. The stock of claim 11 , having a titer of at least about 107 pfu.
14. A composition comprising the recombinant adenovirus of any of claims 1-10 and a pharmacologically acceptable carrier.
15. A recombinant cell line, which produces adenoviral El and DEF -A or DEF-B gene products.
16. A recombinant cell line in which the recombinant adenovirus of claim 1 replicates.
17. The recombinant cell line of claim 16, which produces adenoviral
El gene products and a mutant form of the TBP that recognizes a mutant TATA sequence of the recombinant adenovirus.
18. The recombinant cell line of claim 16, which produces adenoviral El gene products and NF- ATI.
19. The recombinant cell line of claim 16, which produces adenoviral El and one or more L1-L5 gene products.
PCT/US1999/014333 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter WO2000000628A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP99930675A EP1088092A1 (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter
IL14027499A IL140274A0 (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter
AU47163/99A AU4716399A (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter
CA002332181A CA2332181A1 (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter
BR9911539-5A BR9911539A (en) 1998-06-26 1999-06-24 Defective replication recombinant adenoviruses with mutant major late promoter
HU0301318A HUP0301318A2 (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter
PL99345517A PL345517A1 (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter
MXPA00012617A MXPA00012617A (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter.
JP2000557381A JP2002519036A (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with a mutated major late promoter
US09/748,044 US6458578B1 (en) 1998-06-26 2000-12-22 Recombinant cell line produces adenoviral gene products E1 and DEF-A, and/or DEF-B

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/105,515 1998-06-26
US09/105,515 US6113913A (en) 1998-06-26 1998-06-26 Recombinant adenovirus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/105,515 Continuation-In-Part US6113913A (en) 1998-06-26 1998-06-26 Recombinant adenovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/748,044 Continuation US6458578B1 (en) 1998-06-26 2000-12-22 Recombinant cell line produces adenoviral gene products E1 and DEF-A, and/or DEF-B

Publications (2)

Publication Number Publication Date
WO2000000628A1 WO2000000628A1 (en) 2000-01-06
WO2000000628B1 true WO2000000628B1 (en) 2000-03-16

Family

ID=22306280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/014333 WO2000000628A1 (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter

Country Status (12)

Country Link
US (2) US6113913A (en)
EP (1) EP1088092A1 (en)
JP (1) JP2002519036A (en)
AU (1) AU4716399A (en)
BR (1) BR9911539A (en)
CA (1) CA2332181A1 (en)
HU (1) HUP0301318A2 (en)
IL (1) IL140274A0 (en)
MX (1) MXPA00012617A (en)
PL (1) PL345517A1 (en)
TR (1) TR200003803T2 (en)
WO (1) WO2000000628A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11608362B2 (en) 2018-03-06 2023-03-21 Precigen, Inc. Hepatitis B vaccines and uses of the same

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131458A1 (en) * 1998-11-18 2001-09-12 CANJI, Inc. Viral vectors with late transgene expression
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
CA2469491A1 (en) * 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
US20040142864A1 (en) * 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
WO2004050027A2 (en) * 2002-12-02 2004-06-17 Genvec, Inc. Materials and methods for treating ocular-related disorders
JP2006516548A (en) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US20050170431A1 (en) * 2003-02-28 2005-08-04 Plexxikon, Inc. PYK2 crystal structure and uses
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005051432A1 (en) 2003-11-14 2005-06-09 Genvec, Inc. Therapeutic regimen for treating cancer
US20070066641A1 (en) * 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
EP1696920B8 (en) * 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
ES2329607T3 (en) * 2004-02-23 2009-11-27 Crucell Holland B.V. VIRUS PURIFICATION METHODS
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
CN1972958B (en) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 Method of using adenoviral vectors to induce an immune response
US7585859B2 (en) * 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1786813A2 (en) * 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
US20060188481A1 (en) * 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
KR20080027775A (en) * 2005-05-17 2008-03-28 플렉시콘, 인코퍼레이티드 Pyrrole(2,3-b)pyridine derivatives protein kinase inhibitors
CN102603581B (en) * 2005-06-22 2015-06-24 普莱希科公司 Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
EP1929021A2 (en) 2005-08-31 2008-06-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
BRPI0618441B8 (en) 2005-11-10 2021-07-27 Genvec Inc adenoviral vector
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008080001A2 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20081581A1 (en) * 2006-12-21 2008-11-12 Plexxikon Inc PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20090202492A1 (en) * 2008-01-25 2009-08-13 University Of South Florida Adenovirus vaccine utilizing ikk as adjuvant
WO2010060719A1 (en) * 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
PT2387627E (en) 2009-01-15 2016-06-03 Adaptive Biotechnologies Corp Adaptive immunity profiling and methods for generation of monoclonal antibodies
CR20170089A (en) * 2009-04-03 2017-07-17 Plexxikon Inc PROPANE-ACID COMPOSITIONS-1 - SULFONIC {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUORO-PHENIL} -AMIDA AND THE USE OF THE SAME
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US8470585B2 (en) 2009-10-15 2013-06-25 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
JP5393896B2 (en) 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー Method for purifying adenovirus particles
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AU2010314842A1 (en) 2009-11-09 2012-05-31 Genvec, Inc. Methods of propagating monkey adenoviral vectors
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
PL2536829T3 (en) 2010-02-15 2016-09-30 Method for the production of Ad26 adenoviral vectors
TWI688395B (en) 2010-03-23 2020-03-21 英翠克頌公司 Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CN103118702A (en) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 Therapeutic vaccination against active tuberculosis
MX354752B (en) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Heterologous prime boost vaccination regimen against malaria.
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
MA34948B1 (en) 2011-02-07 2014-03-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
RU2631487C2 (en) 2011-05-17 2017-09-22 Плексксикон Инк. Kinases modulation and indications for its use
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP2764012B1 (en) 2011-10-05 2022-02-23 GenVec, Inc. Adenoviral vectors and methods of use
US9580476B2 (en) 2011-10-05 2017-02-28 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
BR112014008249B1 (en) 2011-10-05 2022-03-15 Genvec Inc Adenovirus or adenoviral vector and composition with the same
CN107574154A (en) 2011-10-05 2018-01-12 金维克有限公司 Monkey (gorilla) adenovirus or adenovirus vector and its application method
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
EP2855669B1 (en) 2012-05-29 2018-10-10 GenVec, Inc. Modified serotype 28 adenoviral vectors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20140075201A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
US10017543B2 (en) 2013-03-13 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
KR102236497B1 (en) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble prefusion rsv f polypeptides
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
AP2016009154A0 (en) 2013-09-19 2016-04-30 Crucell Holland Bv Improved adenovirus formulations
TWI710635B (en) 2014-10-09 2020-11-21 美商珍維克公司 Adenoviral vector encoding human atonal homolog-1 (hath1)
RS58080B1 (en) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
JP6887955B2 (en) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Recombinant expression system assay
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
PL3319633T3 (en) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
SG11201804711RA (en) 2015-12-07 2018-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
SI3439672T1 (en) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
JP7233928B2 (en) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine against RSV
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
CN109154000B (en) 2016-05-12 2022-07-05 扬森疫苗与预防公司 Efficient and balanced bidirectional promoters
EA039124B1 (en) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Stabilized pre-fusion rsv f proteins
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
US11155832B2 (en) 2016-09-30 2021-10-26 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into T cells
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
BR112019015671A2 (en) 2017-02-09 2020-04-14 Janssen Vaccines & Prevention Bv potent and short promoter for expression of heterological genes
US20200032223A1 (en) * 2017-04-10 2020-01-30 Epicentrx, Inc. Method for producing recombinant virus
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
MA50502A (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv ADENOVIRUS AND RELATED USES
CN111295391B (en) 2017-10-31 2023-12-05 扬森疫苗与预防公司 Adenovirus and use thereof
JP7438943B2 (en) 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Adenovirus and its uses
PT3743106T (en) 2018-01-23 2022-08-24 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
WO2020216844A1 (en) 2019-04-25 2020-10-29 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
AU2020275455A1 (en) 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
JP2022547107A (en) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー Influenza virus vaccine and its use
JP2022551107A (en) 2019-10-03 2022-12-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Adenoviral vectors and uses thereof
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
TW202144389A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in multiple myeloma and their uses
TW202144388A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in ovarian cancer and their uses
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
FR2704234B1 (en) 1993-04-22 1995-07-21 Centre Nat Rech Scient RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
FR2707664B1 (en) 1993-07-13 1995-09-29 Centre Nat Rech Scient Viral vectors and use in gene therapy.
CA2189067A1 (en) * 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
ATE336587T1 (en) * 1994-06-10 2006-09-15 Genvec Inc ADENOVIRUS VECTOR SYSTEMS AND CELL LINES
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11608362B2 (en) 2018-03-06 2023-03-21 Precigen, Inc. Hepatitis B vaccines and uses of the same

Also Published As

Publication number Publication date
MXPA00012617A (en) 2002-08-20
WO2000000628A1 (en) 2000-01-06
TR200003803T2 (en) 2001-04-20
HUP0301318A2 (en) 2003-08-28
AU4716399A (en) 2000-01-17
BR9911539A (en) 2001-03-20
US6458578B1 (en) 2002-10-01
US6113913A (en) 2000-09-05
IL140274A0 (en) 2002-02-10
EP1088092A1 (en) 2001-04-04
PL345517A1 (en) 2001-12-17
CA2332181A1 (en) 2000-01-06
JP2002519036A (en) 2002-07-02

Similar Documents

Publication Publication Date Title
WO2000000628B1 (en) Replication-defective recombinant adenovirus with mutated major late promoter
Rosa-Calatrava et al. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization
US6080569A (en) Adenovirus vectors generated from helper viruses and helper-dependent vectors
US5919676A (en) Adenoviral vector system comprising Cre-loxP recombination
Fisher et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis
US6120764A (en) Adenoviruses for control of gene expression
Ostapchuk et al. The L4 22-kilodalton protein plays a role in packaging of the adenovirus genome
Marcellus et al. Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis
AU731767B2 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
US6913927B2 (en) Non-adenoviral gene product-based complementing cells for adenoviral vectors
MX9709549A (en) Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses.
ATE196502T1 (en) NEW COMPLEMENTATION CELL LINES FOR DEFECTIVE ADENOVIRAL VECTORS
CA2311643A1 (en) Compositions and methods for inducing gene expression
CA2283231A1 (en) Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1998013499A3 (en) Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
CA2241726A1 (en) Genes and gene products related to werner's syndrome
CA2681966A1 (en) Baculovirus expression system
Elgadi et al. Sequence and sequence analysis of E1 and pIX regions of the BAV3 genome
Hillgenberg et al. System for efficient helper-dependent minimal adenovirus construction and rescue
Gonzalez‐Nicolini et al. Adenoviral vector platform for transduction of constitutive and regulated tricistronic or triple‐transcript transgene expression in mammalian cells and microtissues
Nakanishi et al. Invitro transcription of a chromatin-like complex of major core protein VII and DNA of adenovirus serotype 2
Lamb et al. A DNA element that regulates expression of an endogenous retrovirus during F9 cell differentiation is E1A dependent
Cossons et al. The effect of regulatory sequence elements upon the initiation of DNA replication of the minute virus of mice
Daniell et al. Transcription of adenovirus cores in vitro: major RNA products differ from those made from a DNA template.
US6974694B2 (en) Adenoviruses for control of gene expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 47163/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 508837

Country of ref document: NZ

Ref document number: 140274

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999930675

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012617

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000/03803

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 557381

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09748044

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2332181

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1999930675

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 200208862

Country of ref document: ZA

WWW Wipo information: withdrawn in national office

Ref document number: 1999930675

Country of ref document: EP